SURMOUNT-CN

Study record

Population

210 Chinese adults without diabetes; BMI ≥28 or ≥24 with a weight-related comorbidity.

Read source · Full-text reportParticipants; Figure1

Formulation

Sponsor-provided investigational autoinjectors, with matching placebo.

Read source · Study protocolProtocol p40, sections7.1.1–7.1.2

Route

Subcutaneous.

Read source · Full-text reportInterventions

Dose & frequency

Weekly 2.5 mg initially, increased 2.5 mg every four weeks to assigned 10 or 15 mg; lifestyle counseling accompanied treatment.

Read source · Full-text reportInterventions

Study design

Randomized, double-blind placebo trial; 70/71/69 participants in 10 mg/15 mg/placebo arms.

Read source · Full-text reportRandomization; Table1

Duration

52 treatment weeks plus four weeks of safety follow-up without study treatment.

Read source · Full-text reportInterventions

Reported findings

Weight changes −13.6%/−17.5%/−2.3% including discontinuation; efficacy estimates −14.4%/−19.9%/−2.4% exclude post-discontinuation data.

Read source · Full-text reportCo–Primary End Points; Supplement2 eAppendix2

Adverse events

Serious events: 3/70, 8/71, 6/69. Adverse-event treatment discontinuations: 2/70, 5/71, 1/69; GI-only: 2/70, 3/71, 0/69. No deaths.

Read source · Full-text reportTable3 — 10 mg/15 mg/placebo; treatment plus follow-up

Monitoring

Adverse events, vital signs and laboratory testing; independent adjudication of deaths, cardiovascular events and pancreatitis.

Read source · Full-text reportOutcomes; Statistical Analyses